Pharma Mergers Will Be More Defensive Going Forward, Abbott CEO Says
This article was originally published in The Pink Sheet Daily
Investor wariness on the economic benefit of acquisitions will slow consolidation in the industry, White tells The Economist Pharmaceutical Roundtable. Sanofi-Aventis expects that any further consolidation will result from weakness.
You may also be interested in...
Roche will need partners for its pipeline products, Head of Research Strategy Paul Nakagaki, PhD, said
Merck behaved "responsibly" in its handling of the COX-2 inhibitor Vioxx (rofecoxib), Sen. Orrin Hatch (R-Utah) said near the conclusion of a Nov. 18 Senate Finance Committee hearing on the withdrawn COX-2 inhibitor
Investor maintains that Cobalt Pharmaceuticals' patent challenge could mean a generic version of the ACE inhibitor will be launched in mid-2005. Mylan suggests that Icahn's opposition is motivated in part by desire to cash-in on short position in King.